Status: Recruiting
An Early Phase Trial of RPTR-1-201 in Advanced Solid Tumors
This is an early phase trial designed to evaluate the safety, tolerability, and preliminary antitumor activity of RPTR-1-201 in adults with advanced solid tumors. The trial includes dose escalation and dose expansion parts and will evaluate RPTR-1-201 as monotherapy and in combination with an anti-PD-1 monoclonal antibody.
Participants needed: 150
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Repertoire Immune MedicinesUpdated: Feb 17, 2026Locations: 1
Eligibility criteria
Histologically or cytologically confirmed locally advanced or metastatic solid t... [+4]
History of another malignancy within 3 years before the first dose of trial inte... [+5]